Peliosis hepatis overview: Difference between revisions

Jump to navigation Jump to search
Line 39: Line 39:


==Epidemiology and Demographics==
==Epidemiology and Demographics==
The prevalence of Peliosis hepatis is approximately 0.2 percent of patients with pulmonary tuberculosis and about 22 percent in patients following renal transplant. It is most commonly associated with renal transplants. <ref> https://www.ncbi.nlm.nih.gov/books/NBK554470/</ref><ref>https://www.uptodate.com/contents/peliosis-hepatis#:~:text=The%20reported%20prevalence%20of%20peliosis,2%2C6%2C7%5D<ref>
The prevalence of Peliosis hepatis is approximately 0.2 percent of patients with pulmonary tuberculosis and about 22 percent in patients following renal transplant. It is most commonly associated with renal transplants. <ref> https://www.ncbi.nlm.nih.gov/books/NBK554470/</ref><ref>https://www.uptodate.com/contents/peliosis-hepatis#:~:text=The%20reported%20prevalence%20of%20peliosis,2%2C6%2C7%5D<ref>.
 
==Risk Factors==
 
==Screening==
 
==Natural History, Complications, and Prognosis==
===Natural History===
 
===Complications===
*'''Infections:''' [[HIV]], Bacillary peliosis (caused by genus  ''[[Bartonella]]'', bacteria responsible for [[cat-scratch disease]] which are identified histologically adjacent to the peliotic lesions<ref>{{cite journal |author=Koehler JE, Sanchez MA, Garrido CS, Whitfeld MJ, Chen FM, Berger TG, Rodriguez-Barradas MC, LeBoit PE, Tappero JW |title=Molecular epidemiology of bartonella infections in patients with bacillary angiomatosis-peliosis |journal=N. Engl. J. Med. |volume=337 |issue=26 |pages=1876-83 |year=1997 |pmid=9407154}}</ref>), ''[[Staphylococcus aureus]]''<ref>{{cite journal |author=Perkocha LA, Geaghan SM, Yen TS, Nishimura SL, Chan SP, Garcia-Kennedy R, Honda G, Stoloff AC, Klein HZ, Goldman RL |title=Clinical and pathological features of bacillary peliosis hepatis in association with human immunodeficiency virus infection |journal=N. Engl. J. Med. |volume=323 |issue=23 |pages=1581-6 |year=1990 |pmid=2233946}}</ref>
*'''Chronic conditions:'''  End stage [[renal failure]], [[Kwashiorkor]], [[tuberculosis]] and other chronic infections.
*'''Malignancy:''' [[Monoclonal gammopathy|Monoclonal gammopathies]] ([[multiple myeloma]] and [[Waldenstrom macroglobulinemia]]), [[Hodgkin's disease]], [[malignant histiocytosis]], [[seminoma]], [[hepatocellular adenoma]] and [[Hepatocellular carcinoma|hepatocarcinoma]],<ref>{{cite journal |author=Haboubi NY, Ali HH, Whitwell HL, Ackrill P |title=Role of endothelial cell injury in the spectrum of azathioprine-induced liver disease after renal transplant: light microscopy and ultrastructural observations |journal=Am. J. Gastroenterol. |volume=83 |issue=3 |pages=256-61 |year=1988 |pmid=3278593}}</ref>
* '''Renal transplants:'''  It can be found in up to 20% patients, can be related to azathioprine or cyclosporine use and may be associated with increased risk of [[transplant rejection]]<ref>{{cite journal |author=Izumi S, Nishiuchi M, Kameda Y, Nagano S, Fukunishi T, Kohro T, Shinji Y |title=Laparoscopic study of peliosis hepatis and nodular transformation of the liver before and after renal transplantation: natural history and aetiology in follow-up cases |journal=J. Hepatol. |volume=20 |issue=1 |pages=129-37 |year=1994 |pmid=8201214}}</ref><ref>{{cite journal |author=Cavalcanti R, Pol S, Carnot F, Campos H, Degott C, Driss F, Legendre C, Kreis H |title=Impact and evolution of peliosis hepatis in renal transplant recipients |journal=Transplantation |volume=58 |issue=3 |pages=315-6 |year=1994 |pmid=8053054}}</ref>.
*'''Drugs and toxins:''' [[Corticosteroids]], [[androgens]], [[methyltestosterone]], [[azathioprine]], [[tamoxifen]]<ref>{{cite book | last = Goldman | first = Lee | title = Cecil Textbook of Medicine -- 2-Volume Set, Text with Continually Updated Online Reference | publisher = W.B. Saunders Company | location = Philadelphia | year = 2003 | isbn = 0721645631 }}</ref>
 
===Prognosis===


==Diagnosis==
==Diagnosis==

Revision as of 22:22, 8 November 2020

Peliosis hepatis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Peliosis hepatis from Other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Peliosis hepatis overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Peliosis hepatis overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Peliosis hepatis overview

CDC on Peliosis hepatis overview

Peliosis hepatis overview in the news

Blogs on Peliosis hepatis overview

Directions to Hospitals Treating Peliosis hepatis

Risk calculators and risk factors for Peliosis hepatis overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Overview

Peliosis Hepatis is an uncommon vascular condition characterised by randomly distributed multiple blood-filled cavities throughout liver. Size of the cavities usually ranges between a few millimetres to 3 cm in diameter[1]. In the past it was a mere histological curiosity occasionally found at autopsies but has been increasingly recognised with wide ranging conditions from AIDS to the use of anabolic steroids. It also occasionally affects spleen, lymph nodes, lungs, kidneys, adrenal glands, bone marrow and other parts of gastrointestinal tract.[2].

Peliosis hepatis is often erroneously written "peliosis hepatitis", despite its not being one of the hepatitides. The correct term arises from the Greek pelios, i.e. discoloured by extravasated blood, livid[3], and the Latinized Genitive case (hepatis[4]) of the Greek hepar, liver[5].

Historical Perspective

There is limited information about the historical perspective of Peliosis hepatis

Classification

There is no established system for the classification of Peliosis hepatis

Pathophysiology

The pathogenesis of peliosis hepatis is unknown. There are several hypotheses, such as, it arise from sinusoidal epithelial damage[6], increased sinusoidal pressure due to obstruction in blood outflow from the liver, or hepatocellular necrosis[1].

Two morphologic patterns of hepatic peliosis were described by Yanoff and Rawson [7]. In the phlebectatic type, the blood-filled spaces are lined with endothelium and are associated with aneurismal dilatation of the central vein; in the parenchymal type, the spaces have no endothelial lining and they usually are associated with haemorrhagic parenchymal necrosis. Some considers both pattern to be one process, initiated by focal necrosis of liver parenchyma observed in parenchymal type progressing into formation of fibrous wall and endothelial lining around haemorrhage of phebectatic type. Fibrosis, cirrhosis, regenerative nodules, and tumours may also be seen.

Causes

Peliosis hepatis may be caused by drugs, toxins, chronic wasting disease, malignancy, and infection. Peliosis Hepatitis may develop in individuals with renal or cardiac transplantation, but in about 20-50% of patients, they are no comorbidities.

common causes include

Differentiating Peliosis hepatis from Other Diseases

Peliosis hepatis must be differentiated from Hepatic Adenoma, Hemangioma, Focal Nodular Hyperplasia, Hepatic Abscess, Hypervascular Metastases, and Hepatocellular Carcinoma.[9] Polycystic liver disease, Congenital hepatic fibrosis, Solitary congenital cysts, Hydatid cyst, Von Meyenburg complexes, Caroli disease (type V choledochal cyst).[10]

Epidemiology and Demographics

The prevalence of Peliosis hepatis is approximately 0.2 percent of patients with pulmonary tuberculosis and about 22 percent in patients following renal transplant. It is most commonly associated with renal transplants. [11]

  • Preferred regimen (1): Clarithromycin 500 mg bid for 4 months
  • Preferred regimen (6): Erythromycin 500 mg PO qid for 4 months
  • Preferred regimen (2): Doxycycline 100 mg PO bid for 4 months
  • Special Consideration
  • Severe disease
  • Preferred regimen: Doxycycline 100 mg PO/IV bid for 4 months AND Rifampin 300 mg PO bid for 4 months

Surgery

Prevention

See Also

References

  1. 1.0 1.1 Sleisenger, Marvin (2006). Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Philadelphia: W.B. Saunders Company. ISBN 1416002456. Chapter 80
  2. Ichijima K, Kobashi Y, Yamabe H, Fujii Y, Inoue Y (1980). "Peliosis hepatis. An unusual case involving multiple organs". Acta Pathol. Jpn. 30 (1): 109–20. PMID 7361545.
  3. "Henry George Liddell, Robert Scott, A Greek-English Lexicon". Retrieved 2007-06-11.
  4. "Charlton T. Lewis, Charles Short, A Latin Dictionary". Retrieved 2007-07-02.
  5. "Henry George Liddell, Robert Scott, A Greek-English Lexicon". Retrieved 2007-07-02.
  6. Gushiken FC (2000). "Peliosis hepatis after treatment with 2-chloro-3'-deoxyadenosine". South. Med. J. 93 (6): 625–6. PMID 10881786.
  7. YANOFF M, RAWSON AJ (1964). "PELIOSIS HEPATIS. AN ANATOMIC STUDY WITH DEMONSTRATION OF TWO VARIETIES". Archives of pathology. 77: 159–65. PMID 14088761.
  8. https://www.ajronline.org/doi/10.2214/AJR.05.0167#:~:text=The%20cause%20of%20peliosis%20hepatis,chronic%20wasting%20diseases%20(e.g.%2C%20tuberculosis
  9. https://www.ajronline.org/doi/10.2214/AJR.05.0167#:~:text=The%20cause%20of%20peliosis%20hepatis,chronic%20wasting%20diseases%20(e.g.%2C%20tuberculosis
  10. https://www.ncbi.nlm.nih.gov/books/NBK554470/
  11. https://www.ncbi.nlm.nih.gov/books/NBK554470/

Template:WS Template:WH